Assert-IQ vs Eko Low Ejection Fraction Tool (ELEFT)

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Abbott
VS

AI Verdict

Assert-IQ provides long-term, continuous monitoring for arrhythmia detection via an insertable cardiac monitor, ideal for managing suspected heart rhythm disorders. In contrast, the Eko Low Ejection Fraction Tool (ELEFT) offers non-invasive, AI-powered screening for low ejection fraction during routine physical exams using a digital stethoscope. While both are cardiology AI tools, their distinct methodologies and clinical applications make them complementary rather than direct competitors.

Choose Assert-IQ if…

Choose Assert-IQ if your clinical objective is long-term, continuous monitoring for comprehensive arrhythmia detection in patients with suspected heart rhythm disorders. This insertable cardiac monitor is ideal for identifying infrequent or asymptomatic arrhythmias over several years, providing detailed data for diagnosis and ongoing management.

View Assert-IQ →

Choose Eko Low Ejection Fraction Tool (ELEFT) if…

Choose Eko Low Ejection Fraction Tool (ELEFT) if you need a rapid, non-invasive screening tool to aid in the early detection of low ejection fraction during routine physical examinations. This AI-powered solution, integrated with digital stethoscopes, is best suited for quickly identifying patients at risk for heart failure, prompting timely referrals for more definitive diagnostic testing.

View Eko Low Ejection Fraction Tool (ELEFT) →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Assert-IQ Eko Low Ejection Fraction Tool (ELEFT)
Deployment Subcutaneously implanted device with mobile app connectivity Unknown
FDA Status Cleared AI-estimated Cleared AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Eko Low Ejection Fraction Tool (ELEFT)

Tool B (ELEFT) offers superior usability due to its non-invasive nature, integrating with a standard digital stethoscope for rapid results during routine physical exams. In contrast, Tool A (Assert-IQ) requires a minimally invasive surgical procedure for insertion, which inherently presents a higher barrier to immediate use for both patients and clinicians.

Clinical Value

Assert-IQ

Tool A (Assert-IQ) provides long-term, continuous cardiac monitoring for up to six years, offering comprehensive and sustained data for diagnosing and managing complex arrhythmias. While Tool B (ELEFT) is valuable for early, non-invasive screening of low ejection fraction, Tool A's ability to capture episodic events over an extended period offers a deeper and more persistent clinical insight for its specific application.

Pricing & Value

Tie

Both tools utilize an enterprise pricing model that requires direct contact with their respective sales teams for specific details, and neither offers a free trial. The lack of transparent, publicly available pricing information for either product makes a direct comparison of their pricing and value impossible.

Enterprise Readiness

Assert-IQ

Both tools are FDA-cleared and HIPAA compliant, targeting enterprise healthcare systems. However, Abbott Medical, the company behind Tool A, is a global, well-established medical device leader with extensive experience in large-scale deployments and robust enterprise support infrastructure. Tool A's hybrid deployment also offers potential flexibility for diverse IT environments, which can be critical for large health systems.

Innovation

Eko Low Ejection Fraction Tool (ELEFT)

Tool B (ELEFT) demonstrates greater innovation by integrating an AI algorithm into a common, non-invasive diagnostic tool like a digital stethoscope for rapid, early detection of low ejection fraction. This approach makes advanced cardiac screening more accessible and efficient within routine physical exams. Tool A, while offering advanced features for an Insertable Cardiac Monitor, builds upon an existing device category.

Support & Docs

Assert-IQ

While specific details on support and documentation are not provided for either tool in the structured facts, Abbott Medical (Tool A) is a global, long-standing leader in the medical device industry. This extensive history and scale strongly suggest a more mature, comprehensive, and widely available support system and documentation compared to a relatively newer company like Eko Health (Tool B).

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Assert-IQ Eko Low Ejection Fraction Tool (ELEFT)
Product Name Assert-IQ Eko Low Ejection Fraction Tool (ELEFT)
Company Abbott Medical Eko Health
Primary Use Case Long-term, continuous monitoring and advanced arrhythmia detection to aid physicians in diagnosing and managing patients with suspected heart rhythm disorders. FDA-cleared AI algorithm that integrates with Eko digital stethoscopes to aid clinicians in the early detection of low ejection fraction, a key indicator of heart failure, during routine physical exams.
Core Detection Focus Advanced arrhythmia detection Low ejection fraction detection
Required Hardware/Integration Insertable Cardiac Monitor (ICM) Eko digital stethoscopes
Target Market Large health systems, hospitals, cardiology clinics Enterprise (implied by 'enterprise solution')

Videos

Demos, reviews, and walkthroughs featuring Assert-IQ and Eko Low Ejection Fraction Tool (ELEFT).

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

The Assert-IQu2122 Insertable Cardiac Monitor system is designed for long-term, continuous monitoring and advanced arrhythmia detection to help diagnose and manage patients with suspected heart rhythm disorders. In contrast, the Eko Low Ejection Fraction Tool (ELEFT) is an AI algorithm that aids clinicians in the early detection of low ejection fraction, a key indicator of heart failure, during routine physical exams.
Assert-IQu2122 is a minimally invasive insertable cardiac monitor that provides long-term continuous cardiac monitoring for up to six years. The ELEFT is a non-invasive screening tool that integrates with digital stethoscopes to analyze ECG and heart sound recordings, providing results in approximately 15 seconds during a physical exam.
The Assert-IQu2122 system requires the insertion of the Assert-IQu2122 Insertable Cardiac Monitor (ICM) device. The ELEFT algorithm, on the other hand, integrates with FDA-cleared Eko digital stethoscopes for its functionality.
Assert-IQu2122 is primarily designed to support Cardiology and Internal Medicine specialties. The ELEFT tool supports Cardiology, Family Medicine, and Internal Medicine, aiding a broader range of clinicians in early heart failure detection.
Assert-IQu2122 uses advanced AI algorithms for arrhythmia detection and transmits data via Bluetoothu00ae Low Energy to a secure cloud-based platform, offering remote monitoring and proactive clinician alerts. ELEFT employs an FDA-cleared AI algorithm to analyze ECG and heart sound recordings, with cloud-based data processing and storage as part of the SENSORAu2122 platform.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.